Mark J. Murray
Director/Board Member at Genevant Sciences Corp.
Network origin in Mark J. Murray first degree
| Entity | Entity type | Industry | |
|---|---|---|---|
| Public Company | Pharmaceuticals: Major | 44 | |
Protiva Biotherapeutics, Inc.
 Protiva Biotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Protiva Biotherapeutics, Inc. develops pharmaceutical products for human diseases. The firm offers drugs for cancer, influenza (including H5N1), Ebola, inflammatory diseases and other chronic viral infections. The company was founded in September, 2000 and is headquartered in Seattle, WA.
7
| Extinct | Pharmaceuticals: Major | 7 |
Genevant Sciences Corp.
 Genevant Sciences Corp. Pharmaceuticals: MajorHealth Technology Part of Roivant Sciences Ltd., Genevant Sciences Corp. operates as a Canadian biopharmaceutical company. The company is based in Burnaby, Canada. The CEO of the company is Bo Rode Hansen.
5
| Subsidiary | Pharmaceuticals: Major | 5 |
Chart of Companies connected to the second degree
Multi-company connection
Companies connected to Mark J. Murray via their personal network
| Company | Sector | Related people | Main position |
|---|---|---|---|
| GILEAD SCIENCES, INC. | Biotechnology | Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal | |
Immunex Corp.
 Immunex Corp. BiotechnologyHealth Technology Immunex Corporation is a leading biopharmaceutical company dedicated to improving lives through immune system science innovation | Biotechnology | Chief Operating Officer Sales & Marketing | |
Sumitomo Pharma America, Inc.
 Sumitomo Pharma America, Inc. Pharmaceuticals: MajorHealth Technology Sumitomo Pharma America, Inc. operates as a biopharmaceutical company that develops pharmaceutical products. Its products include Aptiom (eslicarbazepine acetate) tablets, Latuda (lurasidone HCl) tablets, Lunesta (eszopiclone) tablets, Xopenex (levalbuterol HCl) Inhalation Solution, Xopenex HFA (levalbuterol tartrate) Inhalation Aerosol, Brovana (arformoterol tartrate) Inhalation Solution, Omnaris (ciclesonide) Nasal Spray, Alvesco (ciclesonide) Inhalation Aerosol, and Zetonna (ciclesonide) Nasal Aerosol. The company was founded in 1984 and is headquartered in Marlborough, MA. | Pharmaceuticals: Major | Chief Executive Officer Director of Finance/CFO | |
| DYNAVAX TECHNOLOGIES CORPORATION | Biotechnology | Director/Board Member Director/Board Member | |
| INMED PHARMACEUTICALS INC. | Pharmaceuticals: Major | Director/Board Member Chief Executive Officer | |
QVT Financial LP
 QVT Financial LP Investment ManagersFinance QVT Financial LP is an independent, SEC-registered investment advisor and hedge fund manager headquartered in New York City. The firm was founded in 2003 by Daniel Gold. QVT Financial provides administrative and/or investment management services to private funds including US limited partnerships, non-US limited partnerships and non-US Corporation. | Investment Managers | Portfolio Manager-Equities Analyst-Equity | |
Pharmasset, Inc.
 Pharmasset, Inc. Pharmaceuticals: OtherHealth Technology Pharmasset, Inc. developed drugs to treat viral infections. It focued in the development of oral therapeutics for the treatment of hepatitis C virus (HCV) infection. The company was founded in 1998 and was headquartered in Princeton, NJ. | Pharmaceuticals: Other | Sales & Marketing Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal | |
EMulate Therapeutics, Inc.
 EMulate Therapeutics, Inc. Medical SpecialtiesHealth Technology EMulate Therapeutics, Inc. is a clinical-stage therapeutic device company, which engages in the business of developing noninvasive therapies for cancers and other serious diseases. The firm is also involved in developing treatments for multiple disease areas that affect human health. The company was founded by Bennett Mike Butters and John Kingma on February 7, 2002 and is headquartered in Bellevue, WA. | Medical Specialties | Director/Board Member Director/Board Member | |
| EUPRAXIA PHARMACEUTICALS INC. | Biotechnology | Director of Finance/CFO Corporate Officer/Principal Chief Tech/Sci/R&D Officer | |
Arbutus Biopharma, Inc.
 Arbutus Biopharma, Inc. BiotechnologyHealth Technology Arbutus Biopharma, Inc. engages in the research and development of pharmaceutical products for Hepatitis B. Its operation includes covalently closed circular DNA, Capsid Assembly, Cyclophilins, and Surface Antigen. The company was founded by Patrick T. Higgins, Michael J. Sofia, Michael J. McElhaugh, and Bryce A. Roberts in May 2012 and is headquartered in Doylestown, PA. | Biotechnology | Director/Board Member Director/Board Member Founder Director/Board Member Founder Chief Executive Officer Chief Executive Officer | |
| XENON PHARMACEUTICALS INC. | Pharmaceuticals: Major | Director/Board Member Chief Executive Officer Public Communications Contact | |
| Massachusetts Institute of Technology | College/University | Masters Business Admin Doctorate Degree | |
| Rutgers State University of New Jersey | College/University | Undergraduate Degree Undergraduate Degree | |
| University of British Columbia | College/University | Corporate Officer/Principal Undergraduate Degree Graduate Degree Undergraduate Degree Doctorate Degree Undergraduate Degree | |
| Simon Fraser University | College/University | Corporate Officer/Principal Undergraduate Degree Undergraduate Degree | |
| University of Western Ontario | College/University | Masters Business Admin Masters Business Admin | |
| University of Victoria | College/University | Masters Business Admin Undergraduate Degree | |
| Georgetown University | College/University | Undergraduate Degree Doctorate Degree | |
| MANY BRIGHT IDEAS TECHNOLOGIES INC. | Medical/Nursing Services | Director/Board Member Director/Board Member | |
MPEX Pharmaceuticals, Inc.
 MPEX Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services MPEX Pharmaceuticals, Inc. develops and manufactures therapies for antibiotic resistance with focus on gram-negative organisms. It offers Aeroquin (MP- 376), an aerosol formulation of levofloxacin for the treatment of pulmonary infections in patients with cystic fibrosis, as well as antibiotic programs to address antibiotic resistance in gram negative organisms. The company was founded in 2001 and is headquartered in San Diego, CA. | Miscellaneous Commercial Services | Director/Board Member Chief Executive Officer | |
Eutropics Pharmaceuticals, Inc.
 Eutropics Pharmaceuticals, Inc. Internet Software/ServicesTechnology Services Eutropics Pharmaceuticals, Inc. operates as a biomarker technology platform for accelerating drug discovery and development. The private company is based in Cambridge, MA. The company was founded in 2005 by Gary E. Frashier, Michael Cardone. Michael Cardone has been the CEO since 2005. | Internet Software/Services | Founder Chief Operating Officer | |
The Centre for Drug Research & Development
 The Centre for Drug Research & Development Miscellaneous Commercial ServicesCommercial Services Center for Drug Research & Development operates as a drug development and commercialization company. The firm provides the specialized expertise and infrastructure to identify, validate and advance promising discoveries, and transform them into commercially viable investment opportunities for the private sector and ultimately into new therapies for patients. The company was founded in 2007 and is headquartered in Vancouver, Canada. | Miscellaneous Commercial Services | Director/Board Member Public Communications Contact Human Resources Officer | |
| Harvard Business School | College/University | Masters Business Admin Masters Business Admin | |
Pulmocide Ltd.
 Pulmocide Ltd. Pharmaceuticals: MajorHealth Technology Pulmocide Ltd. provides biopharmaceutical services. It develops inhaled medicines for viral and fungal infections of the respiratory tract. The company was founded by William Garth Rapeport, John Murray, Kazuhiro Ito, and Peter Strong on March 23, 2007 and is headquartered in London, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member Chief Executive Officer | |
| SIO GENE THERAPIES INC. | Pharmaceuticals: Major | Director/Board Member Chairman Chief Executive Officer | |
Axovant Sciences, Inc.
 Axovant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Part of Sio Gene Therapies, Inc., Axovant Sciences, Inc. is a company that manufactures and distributes pharmaceutical products. The company is based in New York, NY. | Pharmaceuticals: Major | Chairman Chief Executive Officer | |
Myovant Sciences, Inc.
 Myovant Sciences, Inc. Medical SpecialtiesHealth Technology Myovant Sciences, Inc. offers therapeutics for women's health and prostate cancer. The company is headquartered in New York, NY. | Medical Specialties | President Director/Board Member | |
| MYOVANT SCIENCES LTD. | Biotechnology | Director of Finance/CFO Chairman Director/Board Member Director/Board Member Chairman | |
Dermavant Sciences, Inc.
 Dermavant Sciences, Inc. BiotechnologyHealth Technology Part of Roivant Sciences Ltd., Dermavant Sciences, Inc. develops biological products. The company is based in Raleigh, NC. Todd Zavodnick has been the CEO of the company since 2018. | Biotechnology | Director/Board Member Chairman | |
Roivant Sciences, Inc.
 Roivant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Roivant Sciences, Inc. operates as a pharmaceutical firm. It develops and markets drugs. The firm specializes in uterine fibroids, endometriosis, prostate cancer, diabetes, and pulmonary arterial hypertension. The company was founded by Vivek Ramaswamy in 2014 and is headquartered in New York, NY. | Pharmaceuticals: Major | Corporate Officer/Principal Director/Board Member Corporate Officer/Principal Chief Executive Officer Corporate Officer/Principal | |
Urovant Sciences, Inc.
 Urovant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Part of Sumitomo Chemical Co., Ltd., Urovant Sciences, Inc. is a pharmaceutical company that prioritizes diversity, equity, and inclusion in rewriting how care is provided in urology. The company is based in Irvine, CA and offers programs to improve patient care, with a current focus on overactive bladder. Urovant Sciences is expanding opportunities to help patients in and beyond, with links to marketed product sites for patients and healthcare professionals, plus patent information. Recently, Sumitovant Biopharma Ltd. announced that its parent company Sumitomo Pharma Co., Ltd. will combine its wholly owned subsidiaries to form Sumitomo Pharma America, Inc., which will include Urovant Sciences and other subsidiaries. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| UROVANT SCIENCES LTD. | Pharmaceuticals: Major | Chairman Director/Board Member | |
| NERVGEN PHARMA CORP. | Pharmaceuticals: Major | Director/Board Member Chief Executive Officer | |
Altavant Sciences, Inc.
 Altavant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Altavant Sciences, Inc. is a clinical stage biopharmaceutical company, which provides therapies that treat respiratory diseases with an initial therapeutic focus in pulmonary arterial hypertension (PAH). The company is headquartered in Cary, NC. | Pharmaceuticals: Major | Director/Board Member Director/Board Member Chief Executive Officer | |
Dermavant Sciences Ltd.
 Dermavant Sciences Ltd. Pharmaceuticals: MajorHealth Technology Dermavant Sciences Ltd. is a clinical-stage biopharmaceutical company which focuses on developing and commercializing therapeutics in medical dermatology. The company is developing a pipeline of therapies in medical dermatology and is currently advancing development programs for five product candidates which targets specific unmet needs in two of the immuno-dermatology markets, psoriasis and atopic dermatitis, as well as other large markets, including vitiligo, primary focal hyperhidrosis and acne. The company was founded on September 28, 2015 and is headquartered in London, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member Chairman | |
Genevant Sciences, Inc.
 Genevant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Genevant Sciences, Inc. is a company based in Cambridge, MA that specializes in nucleic acid drug development and delivery. The company has developed lipid nanoparticle (LNP) technology and next-generation ligand conjugate technology for delivery of gene editing payloads, small interfering RNA (siRNA), and other oligonucleotide payloads. The company has a robust and expansive LNP patent estate and decades of experience and expertise in nucleic acid drug development. The company is committed to maximizing every opportunity to transform the future of human health by expanding their focus to extrahepatic tissues and cell types, such as the lung, stellate cells, and leukocytes. Genevant Sciences has built expertise in siRNA payload design and development and has more than 700 patents worldwide that they own or license. The company is open, collaborative, and entrepreneurial, and are always ready to connect with people interested in the pioneering work they do. | Pharmaceuticals: Major | President Chief Executive Officer | |
| PERIMETER MEDICAL IMAGING AI, INC. | Medical Specialties | Director/Board Member Investor Relations Contact |
Statistics
International
| United States | 26 |
| Canada | 21 |
| United Kingdom | 5 |
| France | 2 |
Sectoral
| Health Technology | 35 |
| Consumer Services | 8 |
| Finance | 5 |
| Commercial Services | 4 |
| Health Services | 2 |
Operational
| Director/Board Member | 262 |
| Corporate Officer/Principal | 100 |
| Independent Dir/Board Member | 63 |
| President | 61 |
| Chief Executive Officer | 58 |
Most connected contacts
| Insiders | |
|---|---|
| Myrtle Potter | 42 |
| Frank Torti | 35 |
| Ken Galbraith | 30 |
| Dan Kisner | 29 |
| Daniel Burgess | 28 |
| R. MacKay-Dunn | 26 |
| Gary E. Frashier | 26 |
| Ronald Ian Lennox | 22 |
| Robert S. Whitehead | 22 |
| Michael Jeffrey Abrams | 16 |
| Adam Daniel Cutler | 16 |
| Richard Henriques | 15 |
| Keith Manchester | 15 |
| Bruce Cousins | 14 |
| Vivek Ramaswamy | 14 |
- Stock Market
- Insiders
- Mark J. Murray
- Company connections
